At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
GSK1278863 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).
In Brief
A Phase 2 clinical trial evaluating GSK1278863 and Placebo for Vascular Disease, Peripheral. Completed, enrolled 46 participants across 12 sites.
Detailed Summary
This is a multi-center, randomized, blinded, placebo controlled study to evaluate the safety of GSK1278863 and its acute and short-term (e.g. 14d) effects on calf muscle endurance and walking ability in subjects with PAD and symptomatic claudication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVascular Disease, Peripheral
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
Primary CompletionNov 2011
First PostedMay 2014
TodayJul 2026
First PostedMay 12, 2014
Enrollment StartOct 15, 2010
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 12.1 years ago
Interventions
GSK1278863drug
GSK1278863
Placebodrug
Placebo